Interim

Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected

Retrieved on: 
Friday, May 3, 2024
Annual general meeting, Sale, Annual, Self-publishing, Invitation, Proxy, ART, CHF, Interim, Bank statement, AGM, Holding company

Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected

Key Points: 
  • Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected
    PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART.
  • Reinach, Switzerland, 12 April 2024 — Evolva Holding SA in liquidation (SIX: EVE) (“Evolva”) today held its Annual General Meeting (“AGM”) in Basel.
  • The shareholders approved the proposals put forward by the board of directors with large majorities.
  • They also approved Nice & Green SA’s proposals to revoke the liquidation resolution and the delisting resolution, but rejected the proposal to introduce an opting-out clause in the articles of association.

EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth

Retrieved on: 
Friday, May 3, 2024
Science, Annual general meeting, EDT, Investment, PIN, Paris Agreement, EVT201, HR, Partnership, Growth, Targets, Insomnia, Webcast, Janssen, Evotec, Novartis, Science Based Targets initiative, Just, Supervisory board, Interim, BMS, Medicine, Capsule

Just – Evotec Biologics contributed € 108.4 m to the total group revenue compared to € 51.3 m in 2022, reflecting a 111% growth.

Key Points: 
  • Just – Evotec Biologics contributed € 108.4 m to the total group revenue compared to € 51.3 m in 2022, reflecting a 111% growth.
  • In March 2023, BMS and Evotec extended and expanded the neurodegeneration partnership, originally signed in 2016, for an additional eight years.
  • Evotec plans to update the market on its mid-term forecast with the release of its H1 2024 results in August 2024.
  • As part of this priority reset and in line with market developments, Evotec will simplify its reporting to Shared R&D and Just – Evotec Biologics starting Q1 2024.

MGI – Media and Games Invest SE Reschedules Publication of Interim Report Q1 2024 from May 30, 2024 to May 07, 2024

Retrieved on: 
Friday, May 3, 2024
Remco, Media, Interim, CFO, MGI

MGI – Media and Games Invest SE Reschedules Publication of Interim Report Q1 2024 from May 30, 2024 to May 07, 2024

Key Points: 
  • MGI – Media and Games Invest SE Reschedules Publication of Interim Report Q1 2024 from May 30, 2024 to May 07, 2024
    May 03, 2024, 14:20 CEST: MGI – Media and Games Invest SE (“MGI” or the “Company”, ISIN: SE0018538068; Ticker M8G; Nasdaq First North Premier Growth Market and Scale Segment Frankfurt Stock Exchange) announces a new date for the publication of its Interim Report Q1 2024.
  • MGI – Media and Games Invest SE will publish its Interim Report Q1 2024 on May 07, 2024 at 08:00 CEST instead of on May 30, 2024.
  • The company invites investors to participate in the presentation of the Q1 results by Remco Westermann (CEO) and Paul Echt (CFO) on Tuesday, May 07, 2024 at 13:00 CEST.
  • The presentation will be held in English and will also be available on-demand on the Company’s website www.mgi-se.com .

EQS-News: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024

Retrieved on: 
Friday, May 3, 2024
USD, Sale, FDA, CFO, ATAC, Multiple myeloma, CAIX, Priority review, Teaching, Food, Research, Depreciation, BCMA, EUR, Biologics license application, Disease, ADC, Research and development, Patient, Chemistry, Supervisory board, BLA, Diagnosis, Marketing, Interim, Bank statement, Clinical trial, ODD, HPHA, Pharmaceutical industry

Ladenburg, Germany, 25 April 2024 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2024 (1 December 2023 – 29 February 2024) and the Group’s financial figures.

Key Points: 
  • Ladenburg, Germany, 25 April 2024 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2024 (1 December 2023 – 29 February 2024) and the Group’s financial figures.
  • Professor Pahl has been Head of Research & Development at Heidelberg Pharma since 2012 and has been a member of the Executive Management Board since 2016.
  • The Heidelberg Pharma Group – as of the reporting date comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The complete figures for the interim financial statements can be downloaded from http://www.heidelberg-pharma.com/ ”Press & Investors > Announcements > Financial Reports > Interim management statement on the first three months of 2024".

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME

Retrieved on: 
Thursday, May 2, 2024
CFO, LLP, Prior, News, Interim management, Pomerantz, SVP, Senior, Interim, Zymeworks

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).

Key Points: 
  • NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME).
  • 7980
    The investigation concerns whether Zymeworks and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Genmab Announces Financial Results for the First Quarter of 2024

Retrieved on: 
Thursday, May 2, 2024
USD, FDA, Pfizer, EDT, Priority review, AbbVie, Food, Risk, Annual report, Johnson & Johnson, DKK, Janssen, U.S. FDA, Risk management, Environment, Rituximab, Follicular lymphoma, Novartis, PDUFA, ADC, Patient, Acquisition, Interim, Lenalidomide, Daratumumab, Priority, BST, Pharmaceutical industry

Genmab is maintaining its 2024 financial guidance published on February 14, 2024.

Key Points: 
  • Genmab is maintaining its 2024 financial guidance published on February 14, 2024.
  • We expect to update our guidance no later than in connection with our second quarter 2024 earnings.
  • Genmab will hold a conference call to discuss the results for the first quarter of 2024 today, Thursday, May 2, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT.
  • Actual results or performance may differ materially from any future results or performance expressed or implied by such statements.

JOANN Receives Court Approval for Prepackaged Financial Recapitalization Plan

Retrieved on: 
Thursday, April 25, 2024
Bankruptcy, Lazard, Security (finance), Corporate action, United States bankruptcy court, Interim, Creativity, Latham & Watkins

HUDSON, Ohio, April 25, 2024 (GLOBE NEWSWIRE) -- JOANN Inc. (“JOANN” or the “Company”), the nation’s category leader in sewing and fabrics with one of the largest arts and crafts offerings, today announced that the U.S. Bankruptcy Court for the District of Delaware has confirmed the Company’s Prepackaged Joint Plan of Reorganization.

Key Points: 
  • HUDSON, Ohio, April 25, 2024 (GLOBE NEWSWIRE) -- JOANN Inc. (“JOANN” or the “Company”), the nation’s category leader in sewing and fabrics with one of the largest arts and crafts offerings, today announced that the U.S. Bankruptcy Court for the District of Delaware has confirmed the Company’s Prepackaged Joint Plan of Reorganization.
  • JOANN expects to successfully complete its financial restructuring and emerge from the court-supervised process in the coming days.
  • Latham & Watkins LLP is serving as legal counsel to JOANN, with Houlihan Lokey serving as financial advisor and Alvarez & Marsal North America, LLC serving as restructuring advisor.
  • Gibson Dunn & Crutcher LLP is serving as legal counsel to certain of the Company’s term lenders, with Lazard serving as financial advisor.

Park Aerospace Corp. Announces Election of Chris Goldner as Vice President-Finance and the Planned Retirement of Matt Farabaugh as the Company’s Long Time CFO

Retrieved on: 
Thursday, April 25, 2024
Unmanned aerial vehicle, Hasbro, Business administration, Retirement, CPA, AFP, Senior, Interim, Park Aerospace Corp, Balanced budget, Management

Park also announced that P. Matthew Farabaugh (“Matt”), the Company’s long time Senior Vice President and Chief Financial Officer, plans to retire from the Company at the end of May 2024.

Key Points: 
  • Park also announced that P. Matthew Farabaugh (“Matt”), the Company’s long time Senior Vice President and Chief Financial Officer, plans to retire from the Company at the end of May 2024.
  • Matt joined the Company in October of 2007 and has served as the Company’s CFO since April 2012.
  • Chris started with Park on March 4, 2024 and has been working with Matt and Park’s accounting staff for the last two months to facilitate the transition.
  • Upon Matt’s retirement, Chris will report to Brian Shore, the Company’s Chairman and CEO, and Chris will serve as the Company’s principal financial officer.

Cook County Health’s Correctional Health Program at Cook County Jail Accredited for Quality Health Care Services

Retrieved on: 
Thursday, April 25, 2024
Public, CCH, Pharmacy, Dental care, Health promotion, National Commission, Health, Safety, Risk, International Patient Safety Goals, Cook County Jail, Cook County Sheriff, Prison, CCHP, Environment, Accreditation, Patient, Mental health, Work, Physician, Interim, Mental, Medical director, Excellence, Nursing

Chicago, IL, April 25, 2024 (GLOBE NEWSWIRE) -- Cook County Health’s (CCH) Cermak Health Services has earned accreditation from the National Commission on Correctional Health Care (NCCHC) for demonstrating full compliance with NCCHC’s nationally recognized standards of care for correctional health services in jails.

Key Points: 
  • Chicago, IL, April 25, 2024 (GLOBE NEWSWIRE) -- Cook County Health’s (CCH) Cermak Health Services has earned accreditation from the National Commission on Correctional Health Care (NCCHC) for demonstrating full compliance with NCCHC’s nationally recognized standards of care for correctional health services in jails.
  • Cermak Health Services was recognized for its ongoing commitment to providing quality health services for the patients at Cook County Jail.
  • “Providing exceptional health care services in correctional health facilities is a critical component of public health in Cook County.
  • This accreditation reaffirms our mission to offer equitable, comprehensive care to all, regardless of their circumstances.”
    “Accreditation from the National Commission on Correctional Health Care is reflective of what Cook County Health stands for – which is that every individual has the right to receive quality, compassionate health care,” said Dr. Erik Mikaitis, Interim CEO of Cook County Health.

Silicon Motion Announces Chief Financial Officer Transition

Retrieved on: 
Thursday, April 25, 2024
Silicon Motion, Interim, Motion, Silicon, SIMO, FP

TAIPEI, Taiwan and MILPITAS, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion” or the “Company”) today announced that Jason Tsai, currently VP of IR and Finance at Silicon Motion, has been appointed Interim Chief Financial Officer of the Company effective as of April 25, 2024.

Key Points: 
  • TAIPEI, Taiwan and MILPITAS, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion” or the “Company”) today announced that Jason Tsai, currently VP of IR and Finance at Silicon Motion, has been appointed Interim Chief Financial Officer of the Company effective as of April 25, 2024.
  • Mr. Jason Tsai succeeds Mr. Riyadh Lai who will be stepping down as Chief Financial Officer, effective as of April 25, 2024.
  • Wallace Kou, Chief Executive Officer of Silicon Motion, said, “We are thankful for Riyadh and his many contributions to Silicon Motion as its Chief Financial Officer for more than 17 years.
  • He has demonstrated successes in key financial and operational disciplines, including experience in finance, FP&A, and strategic planning.”
    The Company has initiated a search process for the permanent Chief Financial Officer position.